UA69396C2 - ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА З ДИСКРЕТНИМ ВИВІЛЬНЕННЯМ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ (ВАРІАНТИ) ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (ВАРІАНТИ) І СПОСІБ ЛІКУВАННЯ (ВАРІАНТИ) - Google Patents
ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА З ДИСКРЕТНИМ ВИВІЛЬНЕННЯМ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ (ВАРІАНТИ) ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (ВАРІАНТИ) І СПОСІБ ЛІКУВАННЯ (ВАРІАНТИ) Download PDFInfo
- Publication number
- UA69396C2 UA69396C2 UA2000063359A UA00063359A UA69396C2 UA 69396 C2 UA69396 C2 UA 69396C2 UA 2000063359 A UA2000063359 A UA 2000063359A UA 00063359 A UA00063359 A UA 00063359A UA 69396 C2 UA69396 C2 UA 69396C2
- Authority
- UA
- Ukraine
- Prior art keywords
- layer
- dosage form
- inhibitor
- core material
- enteric coating
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 66
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims abstract description 29
- 229940121819 ATPase inhibitor Drugs 0.000 claims abstract description 27
- 230000003111 delayed effect Effects 0.000 claims abstract description 12
- 239000010410 layer Substances 0.000 claims description 170
- 239000011162 core material Substances 0.000 claims description 77
- 239000006187 pill Substances 0.000 claims description 71
- 238000009505 enteric coating Methods 0.000 claims description 64
- 239000002702 enteric coating Substances 0.000 claims description 64
- 239000000126 substance Substances 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 230000008961 swelling Effects 0.000 claims description 34
- 229960000381 omeprazole Drugs 0.000 claims description 31
- 239000008187 granular material Substances 0.000 claims description 30
- 230000001105 regulatory effect Effects 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 23
- 239000011248 coating agent Substances 0.000 claims description 19
- 238000000576 coating method Methods 0.000 claims description 19
- 239000000945 filler Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 16
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- -1 alkali metal salt Chemical class 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 159000000011 group IA salts Chemical class 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 230000009858 acid secretion Effects 0.000 claims description 4
- 159000000003 magnesium salts Chemical group 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 229960003174 lansoprazole Drugs 0.000 claims description 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000005968 oxazolinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 2
- 230000001276 controlling effect Effects 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- QUJXIMWUJGTUEG-CLKUPZDLSA-N 2-[2-[[[(2s,6s,9e,13s)-13-amino-2-[(4-hydroxyphenyl)methyl]-4,14-dioxo-1,5-diazacyclotetradec-9-ene-6-carbonyl]amino]methyl]phenyl]acetic acid Chemical compound C([C@H]1CC(=O)N[C@@H](CC/C=C/CC[C@@H](C(N1)=O)N)C(=O)NCC=1C(=CC=CC=1)CC(O)=O)C1=CC=C(O)C=C1 QUJXIMWUJGTUEG-CLKUPZDLSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- 239000000203 mixture Substances 0.000 description 60
- 239000000725 suspension Substances 0.000 description 28
- 239000000454 talc Substances 0.000 description 20
- 229910052623 talc Inorganic materials 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 229940124597 therapeutic agent Drugs 0.000 description 19
- 239000013543 active substance Substances 0.000 description 18
- 238000004090 dissolution Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000612 proton pump inhibitor Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000001856 Ethyl cellulose Substances 0.000 description 13
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 13
- 235000019325 ethyl cellulose Nutrition 0.000 description 13
- 229920001249 ethyl cellulose Polymers 0.000 description 13
- 229940126409 proton pump inhibitor Drugs 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- 238000005507 spraying Methods 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 10
- 229940068968 polysorbate 80 Drugs 0.000 description 10
- 229920000053 polysorbate 80 Polymers 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 150000007513 acids Chemical class 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 7
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 239000007942 layered tablet Substances 0.000 description 6
- 229960005019 pantoprazole Drugs 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- 239000001069 triethyl citrate Substances 0.000 description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 4
- 235000013769 triethyl citrate Nutrition 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007931 coated granule Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 3
- 238000005563 spheronization Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000159 acid neutralizing agent Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000004859 neutralization-reionization mass spectrometry Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002357 osmotic agent Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 229910002514 Co–Co Inorganic materials 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000006270 Proton Pumps Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- HKQOBOMRSSHSTC-UHFFFAOYSA-N cellulose acetate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 HKQOBOMRSSHSTC-UHFFFAOYSA-N 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001723 curing Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010013864 duodenitis Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical class [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Chemical class [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 230000017619 regulation of gastric acid secretion Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000000429 sodium aluminium silicate Substances 0.000 description 1
- 235000012217 sodium aluminium silicate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- OKUCEQDKBKYEJY-UHFFFAOYSA-N tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)C1 OKUCEQDKBKYEJY-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9704870A SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | New pharmaceutical formulation I |
| PCT/SE1998/002369 WO1999032093A1 (en) | 1997-12-22 | 1998-12-17 | Oral pharmaceutical pulsed release dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA69396C2 true UA69396C2 (uk) | 2004-09-15 |
Family
ID=20409572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2000063359A UA69396C2 (uk) | 1997-12-22 | 1998-12-17 | ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА З ДИСКРЕТНИМ ВИВІЛЬНЕННЯМ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ (ВАРІАНТИ) ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (ВАРІАНТИ) І СПОСІБ ЛІКУВАННЯ (ВАРІАНТИ) |
Country Status (39)
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| FR2774288B1 (fr) * | 1998-01-30 | 2001-09-07 | Ethypharm Sa | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
| ATE321538T1 (de) | 1998-08-12 | 2006-04-15 | Altana Pharma Ag | Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole |
| JP2000128779A (ja) * | 1998-10-20 | 2000-05-09 | Mitsui Chemicals Inc | 薬物放出制御型製剤 |
| FR2793688B1 (fr) | 1999-05-21 | 2003-06-13 | Ethypharm Lab Prod Ethiques | Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques |
| GB9923045D0 (en) * | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
| GB9923436D0 (en) * | 1999-10-04 | 1999-12-08 | American Home Prod | Pharmaceutical compositions |
| KR100889069B1 (ko) | 1999-10-29 | 2009-03-17 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US7029701B2 (en) * | 2000-09-11 | 2006-04-18 | Andrx Pharmaceuticals, Llc | Composition for the treatment and prevention of ischemic events |
| US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US7157095B2 (en) * | 2000-10-13 | 2007-01-02 | Advancis Pharmaceutical Corporation | Multiple-delayed release antifungal product, use and formulation thereof |
| AU2738302A (en) | 2000-10-30 | 2002-05-15 | Euro Celtique Sa | Controlled release hydrocodone formulations |
| JP2002234842A (ja) * | 2001-02-09 | 2002-08-23 | Kyowa Yakuhin Kogyo Kk | 内服腸溶性製剤 |
| US7316819B2 (en) * | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| US20040253312A1 (en) * | 2001-09-28 | 2004-12-16 | Sowden Harry S. | Immediate release dosage form comprising shell having openings therein |
| US20050163846A1 (en) * | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
| WO2004035052A1 (ja) | 2002-10-16 | 2004-04-29 | Takeda Pharmaceutical Company Limited | 安定な固形製剤 |
| MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| JP2006506461A (ja) * | 2002-10-25 | 2006-02-23 | コルジウム ファーマシューティカル， インコーポレイテッド | ミルナシプランのパルス型放出組成物 |
| AU2003297736A1 (en) * | 2002-12-23 | 2004-07-29 | Celltech Americas, Inc. | Acid labile drug compositions |
| JP2004231520A (ja) * | 2003-01-28 | 2004-08-19 | Nichiko Pharmaceutical Co Ltd | 保存安定性及び溶出速度に優れた医薬組成物 |
| US20040146558A1 (en) * | 2003-01-28 | 2004-07-29 | Kyowa Pharmaceutical Co., Ltd. | Oral enteric-coated preparation |
| JP4933033B2 (ja) * | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
| CA2519208A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2004258953B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| JP2006528185A (ja) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
| AU2004258949B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| CA2535177A1 (en) | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
| US8062672B2 (en) | 2003-08-12 | 2011-11-22 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
| AU2004270170B2 (en) * | 2003-08-29 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| DE502004008834D1 (de) * | 2003-09-03 | 2009-02-26 | Pharmaton Sa | Kapseln enthaltend wirkstoffpellets mit unterschiedlichen freisetzungsprofilen |
| CA2538064C (en) | 2003-09-15 | 2013-12-17 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| NZ546183A (en) * | 2003-09-26 | 2011-04-29 | Alza Corp | Controlled release formulations exhibiting an ascending rate of release |
| MXPA06003453A (es) * | 2003-09-26 | 2006-08-31 | Johnson & Johnson | Barra de empuje oros para el suministro controlado de agentes activos. |
| CA2540308C (en) | 2003-09-26 | 2013-08-06 | Alza Corporation | Drug coating providing high drug loading and methods for providing the same |
| CN102697704A (zh) * | 2003-09-26 | 2012-10-03 | 阿尔扎公司 | 阿片类与非阿片类镇痛药的控释制剂 |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
| NZ549838A (en) * | 2004-03-26 | 2010-04-30 | Eisai R&D Man Co Ltd | Coated controlled-release preparation containing a gastric acid secretion inhibitor |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8461187B2 (en) * | 2004-06-16 | 2013-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
| AU2011205024B2 (en) * | 2004-06-16 | 2012-09-06 | Takeda Pharmaceutical Company Limited | Multiple PPI dosage form |
| CA2572292A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
| US8541026B2 (en) * | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
| AR051654A1 (es) * | 2004-11-04 | 2007-01-31 | Astrazeneca Ab | Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones |
| AR052225A1 (es) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones |
| US7226454B2 (en) * | 2004-12-07 | 2007-06-05 | Arizant Healthcare Inc. | Warming device with varied permeability |
| WO2006111853A2 (en) * | 2005-04-18 | 2006-10-26 | Aurobindo Pharma Limited | Stable solid dosage forms of acid labile drug |
| US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| EP1754471A1 (de) * | 2005-08-18 | 2007-02-21 | ORAMON-Arzneimittel GmbH & Co. KG | Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung |
| US20090148519A1 (en) * | 2005-09-29 | 2009-06-11 | Yasuhiro Zaima | Pulsed-release preparation having improved disintegration properties in vivo |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| RU2496480C2 (ru) * | 2005-12-28 | 2013-10-27 | Такеда Фармасьютикал Компани Лимитед | Твердый препарат с контролируемым высвобождением |
| MY151470A (en) * | 2005-12-28 | 2014-05-30 | Takeda Pharmaceutical | Controlled release solid preparation |
| US9532945B2 (en) * | 2006-04-04 | 2017-01-03 | Kg Acquisition Llc | Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor |
| KR101784001B1 (ko) | 2006-04-04 | 2017-10-23 | 케이지 액퀴지션 엘엘씨 | 항혈소판제와 산 억제제를 포함하는 경구 투여용 약학 조성물 |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| CA2654402A1 (en) * | 2006-06-01 | 2007-12-06 | Adel Penhasi | Multiple unit pharmaceutical formulation |
| PL2046334T3 (pl) * | 2006-07-25 | 2015-02-27 | Vecta Ltd | Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI |
| WO2008062320A2 (en) * | 2006-10-06 | 2008-05-29 | Eisai R&D Management Co., Ltd | Extended release formulations of a proton pump inhibitor |
| ITMI20062290A1 (it) * | 2006-11-28 | 2008-05-29 | Monteres S R L | Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente |
| EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
| GB2461822B (en) * | 2007-03-20 | 2011-09-21 | Isp Investments Inc | Meltable binder for melt granulation and/or pelletization |
| AU2008282900B2 (en) * | 2007-07-27 | 2014-05-22 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
| WO2009049160A1 (en) * | 2007-10-12 | 2009-04-16 | Takeda Pharmaceuticals North America | Methods of treating gastrointestinal disorders independent of the intake of food |
| US20110020439A1 (en) * | 2008-03-24 | 2011-01-27 | Shrenik Annasaheb Kole | Delayed release compositions of duloxetine |
| US9220698B2 (en) | 2008-09-09 | 2015-12-29 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
| EP2445344A4 (en) * | 2009-06-25 | 2013-01-23 | Pozen Inc | METHOD FOR THE TREATMENT OF A PATIENT REQUIRED BY ASPIRIN THERAPY |
| KR20120030106A (ko) | 2009-06-25 | 2012-03-27 | 아스트라제네카 아베 | Ｎｓａｉｄ-연관된 궤양의 발생 위험이 있는 환자의 치료 방법 |
| GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| GB201003731D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
| GB201003734D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| US10029089B2 (en) | 2010-10-15 | 2018-07-24 | Research Foundation For The State University Of New York, The | Compositions and methods for enhancing the biological response to chemical agents and physical stimuli |
| EP2797600A4 (en) | 2011-12-28 | 2015-09-16 | Pozen Inc | IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| JP6905972B2 (ja) * | 2016-02-23 | 2021-07-21 | ニプロ株式会社 | 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法 |
| WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
| KR101884230B1 (ko) * | 2016-02-29 | 2018-08-01 | 주식회사 유영제약 | 에소메프라졸을 포함하는 제제 |
| CN105796531A (zh) * | 2016-04-13 | 2016-07-27 | 中国药科大学 | 一种右旋兰索拉唑择时脉冲控释微丸制剂及其制备方法 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| JP6915258B2 (ja) * | 2016-10-21 | 2021-08-04 | ニプロ株式会社 | 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法 |
| CN109125282B (zh) * | 2018-09-05 | 2020-07-14 | 珠海润都制药股份有限公司 | 一种奥美拉唑肠溶胶囊及其制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| GB8518301D0 (en) * | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US5330982A (en) | 1986-12-17 | 1994-07-19 | Glaxo Group Limited | Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith |
| GB8903564D0 (en) | 1989-02-16 | 1989-04-05 | Rashid Abdul | Drug dispensing device |
| AU629915B2 (en) | 1989-02-16 | 1992-10-15 | British Technology Group Limited | Dispensing device |
| US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
| JPH04273816A (ja) * | 1991-02-26 | 1992-09-30 | Tanabe Seiyaku Co Ltd | パルス放出型有核錠 |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| JPH072650A (ja) | 1993-06-18 | 1995-01-06 | Tanabe Seiyaku Co Ltd | 放出部位制御型製剤 |
| SE9302395D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
| SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| DK0723436T3 (da) | 1994-07-08 | 2001-11-26 | Astrazeneca Ab | Tabletteret flerenhedsdoseringsform |
| SK281803B6 (sk) * | 1994-07-08 | 2001-08-06 | Astra Ab | Orálny entericky potiahnutý prípravok, ktorý obsahuje magnéziovú soľ omeprazolu, a spôsob jeho výroby |
| SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| JPH08157392A (ja) * | 1994-12-01 | 1996-06-18 | Kanegafuchi Chem Ind Co Ltd | 放出制御型製剤 |
| SE9500422D0 (sv) | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| US6132768A (en) | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
| SE9600071D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| AU3290397A (en) * | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| SE9602442D0 (sv) * | 1996-06-20 | 1996-06-20 | Astra Ab | Administration of pharmaceuticals |
-
1997
- 1997-12-22 SE SE9704870A patent/SE9704870D0/xx unknown
-
1998
- 1998-12-08 ZA ZA9811234A patent/ZA9811234B/xx unknown
- 1998-12-09 TW TW087120441A patent/TWI240637B/zh not_active IP Right Cessation
- 1998-12-09 AR ARP980106245A patent/AR017202A1/es unknown
- 1998-12-11 MA MA25384A patent/MA26577A1/fr unknown
- 1998-12-16 DZ DZ980296A patent/DZ2686A1/xx active
- 1998-12-16 TN TNTNSN98230A patent/TNSN98230A1/fr unknown
- 1998-12-17 CZ CZ20002313A patent/CZ299227B6/cs not_active IP Right Cessation
- 1998-12-17 SK SK808-2000A patent/SK284545B6/sk unknown
- 1998-12-17 TR TR2000/01982T patent/TR200001982T2/xx unknown
- 1998-12-17 JP JP2000525085A patent/JP4907765B2/ja not_active Expired - Fee Related
- 1998-12-17 NZ NZ505135A patent/NZ505135A/en unknown
- 1998-12-17 PL PL98341565A patent/PL341565A1/xx unknown
- 1998-12-17 KR KR1020007006907A patent/KR100616027B1/ko not_active Expired - Fee Related
- 1998-12-17 CA CA002315927A patent/CA2315927C/en not_active Expired - Fee Related
- 1998-12-17 HU HU0200618A patent/HUP0200618A3/hu unknown
- 1998-12-17 AU AU19913/99A patent/AU759311B2/en not_active Ceased
- 1998-12-17 ES ES98964632T patent/ES2209240T3/es not_active Expired - Lifetime
- 1998-12-17 CN CNB988137402A patent/CN1245155C/zh not_active Expired - Fee Related
- 1998-12-17 EE EEP200000395A patent/EE04417B1/xx not_active IP Right Cessation
- 1998-12-17 AT AT98964632T patent/ATE252379T1/de not_active IP Right Cessation
- 1998-12-17 BR BR9814389-1A patent/BR9814389A/pt not_active Application Discontinuation
- 1998-12-17 RU RU2000116012/14A patent/RU2205028C2/ru not_active IP Right Cessation
- 1998-12-17 YU YU36600A patent/YU36600A/sh unknown
- 1998-12-17 WO PCT/SE1998/002369 patent/WO1999032093A1/en not_active Ceased
- 1998-12-17 HR HR20000381 patent/HRP20000381B1/xx not_active IP Right Cessation
- 1998-12-17 US US09/555,720 patent/US6610323B1/en not_active Expired - Lifetime
- 1998-12-17 DE DE69819205T patent/DE69819205T2/de not_active Expired - Lifetime
- 1998-12-17 EP EP98964632A patent/EP1043977B1/en not_active Expired - Lifetime
- 1998-12-17 DK DK98964632T patent/DK1043977T3/da active
- 1998-12-17 UA UA2000063359A patent/UA69396C2/uk unknown
- 1998-12-17 ID IDW20001201A patent/ID27040A/id unknown
- 1998-12-17 IL IL13682398A patent/IL136823A/xx not_active IP Right Cessation
- 1998-12-17 PT PT98964632T patent/PT1043977E/pt unknown
- 1998-12-21 MY MYPI98005795A patent/MY130765A/en unknown
- 1998-12-21 EG EG158698A patent/EG23875A/xx active
-
2000
- 2000-06-19 IS IS5541A patent/IS2184B/is unknown
- 2000-06-21 NO NO20003219A patent/NO20003219L/no not_active Application Discontinuation
- 2000-07-17 BG BG104619A patent/BG65008B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA69396C2 (uk) | ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА З ДИСКРЕТНИМ ВИВІЛЬНЕННЯМ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ (ВАРІАНТИ) ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (ВАРІАНТИ) І СПОСІБ ЛІКУВАННЯ (ВАРІАНТИ) | |
| RU2158138C2 (ru) | Фармацевтические лекарственные формы для перорального приема, содержащие ингибитор протонного насоса и средство нестероидной противовоспалительной терапии | |
| CA2737851C (en) | Controlled release preparation | |
| JP5844028B2 (ja) | 抗血小板薬及び酸阻害薬を含む経口剤形 | |
| JP2016164170A (ja) | プロトンポンプ阻害剤を含む制御放出組成物 | |
| CN104080446B (zh) | 干包衣片 | |
| JP2010534721A (ja) | パルス型胃滞留性製剤 | |
| UA69397C2 (uk) | ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА ПОДОВЖЕНОЇ ДІЇ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА СПОСІБ ЛІКУВАННЯ | |
| JP2012518655A5 (https=) | ||
| JP2014533656A5 (https=) | ||
| JP2009517466A5 (https=) | ||
| CA2584419A1 (en) | New modified release tablet formulations for proton pump inhibitors | |
| JPWO2007074909A1 (ja) | 放出制御固形製剤 | |
| RU2467740C2 (ru) | Твердое лекарственное средство с контролируемым высвобождением | |
| KR20110102339A (ko) | 고정용량 복합제용 탐술로신 펠렛 | |
| UA81121C2 (en) | Microcapsules for the delayed, controlled release of perindopril, use thereof for the preparation of pharmaceutical composition and pharmaceutical composition containing microcapsules | |
| CA2547398A1 (en) | Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating | |
| TWI606847B (zh) | 口腔內崩解錠 | |
| MXPA00005895A (en) | Oral pharmaceutical pulsed release dosage form | |
| SA99190969B1 (ar) | صورة جرعة صيدلانية ذات اطلاق نبضي pulsed relrase dosage form تؤخذ عن طريق الفم |